Request to Join
has invited you to join this group
has invited you to join this group
Professor of Medicine at Columbia University College of Physicians and Surgeons
Metabolic Medicine Physician, University College Dublin
Director, Nutrition and Metabolic Research Center; Director, Center for Weight Management at Scripps Clinic
Professor of Medicine & Honorary Consultant Physician at University Hospital, Aintree, Liverpool
Professor of Medicine, Biochemistry and Molecular Biology at University of Calgary Cumming School of Medicine
International Medical Director at Novo Nordisk A/S
Medical Director at The Center for Obesity Medicine at Florida Hospital
Endocrinologist at the University of Colorado School of Medicine
Associate Professor of Medicine at Harvard Medical School
Obesity Medicine Physician at Massachusetts General Hospital and Harvard Medical School
Obesity Medicine Specialist at Baptist Health Medical Group
Professor and Chair in Obesity Research and Management at University of Alberta
President, Nashville Preventive Cardiology, PLLC; Preventive Cardiologist and Clinical Lipidologist; Obesity Expert, About.com
Director, Obesity, Metabolism & Nutrition Institute at Massachusetts General Hospital/ Harvard Medical School
Associate Professor of Nutrition and Epidemiology at Harvard T.H. Chan School of Public Health
Associate Professor, Pediatrics & Center for Community Health at UR Medicine's Golisano Children's Hospital
Associate Director, Obesity Prevention Program at Personalized Preventive Care Service
Co-Director, Center for Weight Management and Metabolic Surgery, Brigham and Women's Hospital; Chief of Endocrinology, Brigham and Women's Faulkner Hospital
Gastroenterology and Hepatology Fellow at Mayo Clinic
Endocrinology Fellow, NSW, Australia
Endocrinologist at University of Rochester Medical Center
General Internal Medicine Fellow at Johns Hopkins
Medical Student at Broad Institute
Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.
We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight.
At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of −5.6 kg; 95% confidence interval, −6.0 to −5.1; P&0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P&0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P&0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group.
In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.)
Professor of Medicine at Columbia University College of Physicians and Surgeons
Metabolic Medicine Physician, University College Dublin
Director, Nutrition and Metabolic Research Center; Director, Center for Weight Management at Scripps Clinic
Professor of Medicine & Honorary Consultant Physician at University Hospital, Aintree, Liverpool
Professor of Medicine, Biochemistry and Molecular Biology at University of Calgary Cumming School of Medicine
International Medical Director at Novo Nordisk A/S
Medical Director at The Center for Obesity Medicine at Florida Hospital
Endocrinologist at the University of Colorado School of Medicine
Associate Professor of Medicine at Harvard Medical School
Obesity Medicine Physician at Massachusetts General Hospital and Harvard Medical School
Obesity Medicine Specialist at Baptist Health Medical Group
Professor and Chair in Obesity Research and Management at University of Alberta
President, Nashville Preventive Cardiology, PLLC; Preventive Cardiologist and Clinical Lipidologist; Obesity Expert, About.com
Director, Obesity, Metabolism & Nutrition Institute at Massachusetts General Hospital/ Harvard Medical School
Associate Professor of Nutrition and Epidemiology at Harvard T.H. Chan School of Public Health
Associate Professor, Pediatrics & Center for Community Health at UR Medicine's Golisano Children's Hospital
Associate Director, Obesity Prevention Program at Personalized Preventive Care Service
Co-Director, Center for Weight Management and Metabolic Surgery, Brigham and Women's Hospital; Chief of Endocrinology, Brigham and Women's Faulkner Hospital
Gastroenterology and Hepatology Fellow at Mayo Clinic
Endocrinology Fellow, NSW, Australia
Endocrinologist at University of Rochester Medical Center
General Internal Medicine Fellow at Johns Hopkins
Medical Student at Broad Institute